Novartis AG (NYSE:NVS) has been assigned a consensus rating of “Hold” from the eighteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $90.94.
A number of equities research analysts have issued reports on NVS shares. JPMorgan Chase & Co. lowered shares of Novartis from a “neutral” rating to an “underweight” rating in a report on Wednesday, January 2nd. Jefferies Financial Group reiterated a “buy” rating and issued a $105.00 target price on shares of Novartis in a research note on Tuesday, December 11th. Guggenheim assumed coverage on Novartis in a research note on Monday, October 8th. They set a “neutral” rating on the stock. Zacks Investment Research upgraded Novartis from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research note on Tuesday, September 18th. Finally, Goldman Sachs Group restated a “neutral” rating on shares of Novartis in a research note on Wednesday, October 10th.
Shares of NYSE:NVS traded down $0.50 during trading on Friday, hitting $87.61. The company’s stock had a trading volume of 89,931 shares, compared to its average volume of 2,352,422. Novartis has a 12 month low of $72.30 and a 12 month high of $94.19. The company has a quick ratio of 0.96, a current ratio of 1.20 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $200.88 billion, a PE ratio of 18.22, a price-to-earnings-growth ratio of 1.85 and a beta of 0.73.
Novartis (NYSE:NVS) last released its earnings results on Thursday, October 18th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.01. Novartis had a net margin of 25.98% and a return on equity of 15.81%. The company had revenue of $12.78 billion for the quarter, compared to analysts’ expectations of $12.88 billion. During the same quarter last year, the business earned $1.29 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year. Analysts expect that Novartis will post 5.22 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Bourgeon Capital Management LLC boosted its position in Novartis by 5.3% in the third quarter. Bourgeon Capital Management LLC now owns 69,463 shares of the company’s stock valued at $5,985,000 after buying an additional 3,490 shares during the last quarter. Raymond James Trust N.A. boosted its position in Novartis by 41.8% in the third quarter. Raymond James Trust N.A. now owns 47,271 shares of the company’s stock valued at $4,072,000 after buying an additional 13,938 shares during the last quarter. Patton Albertson Miller Group LLC purchased a new stake in Novartis in the third quarter valued at approximately $211,000. Aperio Group LLC boosted its position in Novartis by 12.4% in the third quarter. Aperio Group LLC now owns 964,474 shares of the company’s stock valued at $83,099,000 after buying an additional 106,560 shares during the last quarter. Finally, First Fiduciary Investment Counsel Inc. boosted its position in Novartis by 0.3% in the second quarter. First Fiduciary Investment Counsel Inc. now owns 227,371 shares of the company’s stock valued at $17,176,000 after buying an additional 735 shares during the last quarter. Institutional investors and hedge funds own 11.18% of the company’s stock.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.